News | Cardiovascular Surgery | January 11, 2024

Paragonix SherpaPak Recognized for Maximizing Access to the Donor Pool in New Clinical Study

The Journal of Lung and Heart Transplantation (JHLT) has published a real-world study indicating a significant reduction in Primary Graft Dysfunction (PGD), a severe post-transplant complication ― potentially allowing for an increase in donor hearts available for heart transplant patients
 
The Journal of Lung and Heart Transplantation (JHLT) has published a real-world study indicating a significant reduction in Primary Graft Dysfunction (PGD), a severe post-transplant complication ― potentially allowing for an increase in donor hearts available for heart transplant patients

January 11, 2024 — Paragonix Technologies, a pioneer in organ transplant solutions, is proud to announce the publication of new groundbreaking data reflecting the clinical impact of its flagship advanced preservation device, the Paragonix SherpaPak Cardiac Transport System (CTS), to protect and monitor donor hearts from extended criteria donors. In organ transplantation, an extended criteria donor is defined as having perceived risk factors linked to poor subsequent outcomes, for example, those with age >55 or ischemic times exceeding 4 hours, which sometimes leads to rejection of the donor organ. The use of extended criteria donor organs can increase the availability of life-saving transplantable organs, proving to be a valuable solution to those on the waitlist in need of an organ transplant.

The Paragonix SherpaPak CTS is a static hypothermic preservation device intended to protect the donor heart during transit, standardizing the internal environment to maintain a recommended thermal range above freezing, unlike traditionally used ice-cold storage. Published in the esteemed Journal of Heart and Lung Transplantation, this study compared the effectiveness of ice-cold storage against the Paragonix SherpaPak CTS, assessing the post-transplant outcomes of recipients who received an extended criteria donor heart. In the recipient group which utilized the Paragonix SherpaPak, the analysis found a significant reduction of 43% in Primary Graft Dysfunction (PGD), a term used to describe the early dysfunction or failure of the transplanted organ. The results also showed a significant reduction of 55% in Severe PGD, a more severe complication occurring within the first 24 hours post-transplant, shown to significantly impact long-term survival of heart transplant recipients.

“The study finds the Paragonix SherpaPak Cardiac Transport System provides a clinically effective solution to safely increase donor heart utilization. The results provide strong support for the utilization of Paragonix advanced organ preservation technologies with extended criteria donor organs,” said Dr. Andreas Zuckermann, Director for Cardiac Transplantation at the Medical University of Vienna (Austria). “These findings demonstrate that the SherpaPak can be safely utilized to expand the donor pool to keep pace with the demand for heart transplants.”

The key findings of this study included:

  • Significant reduction in post-transplant complications: 13.9% of patients who received an extended criteria donor heart preserved on conventional ice storage reported Severe PGD, compared to 6.2% utilizing the Paragonix SherpaPak CTS (p=0.022).
  • Significant reductions in all post-transplant mechanical circulatory support (37% reduction, p=0.012)
  • Significant reduction in newly placed ECMO/VAD post-transplant (49% reduction, p=0.03) when utilizing the Paragonix SherpaPak CTS
  • 92.9% 1-Year Survival in the Paragonix SherpaPak CTS cohort

The study consisted of 330 patients receiving extended criteria donor hearts, and the data was collected from fifteen transplant centers across the United States from October 2015 to January 2023 as part of the GUARDIAN-Heart Registry. 

“At the end of 2023, over 3,000 patients on the transplant waitlist were still in need of a heart transplant,” said Dr. Lisa Anderson, CEO and President of Paragonix Technologies. “We strive to provide new medical technology to enable transplant physicians to safely expand the donor pool and ultimately increase the number of life-saving heart transplants for all patients in need.”

For more information: www.paragonix.com

 

Related Content

News | Cardiovascular Clinical Studies

April 16, 2024 — CVRx, Inc., a commercial-stage medical device company, announced today the availability of additional ...

Home April 16, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — Transcatheter aortic valve replacement (TAVR) was found to bring no increased risks and was associated ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — People with a buildup of fatty atherosclerotic plaque in the heart’s arteries considered at risk of ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — One of the first studies to attempt to treat early-stage heart failure in patients with Type 2 diabetes ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — The investigational drug ninerafaxstat showed a good tolerability and safety profile, along with ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Administering tranexamic acid (TxA), a drug used to reduce bleeding during heart surgery, topically ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Using a web application to qualify individuals for treatment with a nonprescription statin closely ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — People with a small aortic annulus, a part of the heart’s anatomy where the left ventricle meets the ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 8, 2024 — People with diabetes who had suffered a heart attack derived no clinical benefit from edetate disodium ...

Home April 08, 2024
Home
Subscribe Now